Examining Patient-Specific Responses to PARP Inhibitors in a Novel, Human Induced Pluripotent Stem Cell-Based Model of Breast Cancer

Scientists designed an optimized methodology for high-efficiency reprogramming of primary breast cancer cells and used it to generate hiPSC lines from nine breast cancer patients, including those with luminal hormone receptor-positive, HER2-enriched, and triple-negative breast tumors